Product Name: COT (331-337) pS334
Product Number: PE-04AKB90
| Size: | 200 µg | Price: | 37.00 | |
| 1 mg | $US | 74.00 | ||
| 5 mg | 174.00 |
Peptide Name: COT (331-337) pS334
Product Use: Services as a blocking peptide for use with the COT-pS334 rabbit polyclonal antibody (Cat. No.: AB-PK585) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the kinase catalytic subdomain X region. The effect of its phosphorylation is unclear.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: YPR-pS-AYP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Product Use: Services as a blocking peptide for use with the COT-pS334 rabbit polyclonal antibody (Cat. No.: AB-PK585) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the kinase catalytic subdomain X region. The effect of its phosphorylation is unclear.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: YPR-pS-AYP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1107.13 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: COT - pS334 phosphosite-specific antibody (Cat. No.: AB-PK585)
Peptide Molecular Mass Calculated: 1107.13 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: COT - pS334 phosphosite-specific antibody (Cat. No.: AB-PK585)
Scientific Background: COT (TPL2, MAP3K8) is a protein-serine/threonine kinase of the STE group and STE-Unique family. It is essential in the TLR4 (recognizing LPS) MAPK/ERK-mediated response in the production of pro-inflammatory cytokines. Catalytic activity of COT is lost with the K167R, or D270A mutations. IL-1 stimulated activity is decreased with S62A. This mutation will also inhibit IL-1 stimulated phosphorylation of T290 along with MEK phosphorylation when associated with A400. Full inhibition of IL-1 induced MEK phosphorylation and partial inhibition of autophosphorylation can occur with a T290A mutation. Partial inhibition of MEK phosphorylation and autophosphorylation has occurred with a T290A or T290E mutation. Partial impairment of MEK phosphorylation induced by IL-1 has been observed with a S400A mutation. When COT is associated with A62, a complete loss of T290 and MEK phosphorylation occurs with a S400A mutation.
© Kinexus Bioinformatics Corporation 2017